ARCUTIS BIOTHERAPEUTICS, INC. Increase (Decrease) in Accounts Receivable
ARCUTIS BIOTHERAPEUTICS, INC. (ARQT) reported Increase (Decrease) in Accounts Receivable of $8.93 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-08-05
- ARCUTIS BIOTHERAPEUTICS, INC. increase (decrease) in accounts receivable for the quarter ending 2026-06-30 was $10.79M, a 49.29% decline year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. increase (decrease) in accounts receivable for the quarter ending 2026-03-31 was -$1.85M, a 115.00% decline year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. increase (decrease) in accounts receivable for the quarter ending 2025-12-31 was $31.11M, a 120.25% increase year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. increase (decrease) in accounts receivable for the quarter ending 2025-09-30 was $8.43M, a 49.25% decline year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. increase (decrease) in accounts receivable for fiscal 2025 was $73.16M, a 54.81% increase from fiscal 2024.
- ARCUTIS BIOTHERAPEUTICS, INC. increase (decrease) in accounts receivable for fiscal 2024 was $47.26M, a 172.40% increase from fiscal 2023.
- ARCUTIS BIOTHERAPEUTICS, INC. increase (decrease) in accounts receivable for fiscal 2023 was $17.35M, a 105.12% increase from fiscal 2022.
- ARCUTIS BIOTHERAPEUTICS, INC. increase (decrease) in accounts receivable for fiscal 2022 was $8.46M.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $10.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $8.93M 10-Q · filed 2026-08-05 | $40.05M derived: sum of 3 quarters · filed 2026-08-05 | $48.48M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$1.85M 10-Q · filed 2026-05-06 | $29.26M derived: sum of 2 quarters · filed 2026-05-06 | $37.69M derived: sum of 3 quarters · filed 2026-05-06 | $58.96M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $31.11M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $39.54M derived: sum of 2 quarters · filed 2026-02-25 | $60.81M derived: sum of 3 quarters · filed 2026-08-05 | $73.16M 10-K · filed 2026-02-25 |
| 2025-09-30 | $8.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $29.70M derived: sum of 2 quarters · filed 2026-08-05 | $42.05M 10-Q · filed 2025-10-28 | $56.18M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $21.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $33.62M 10-Q · filed 2026-08-05 | $47.75M derived: sum of 3 quarters · filed 2026-08-05 | $64.36M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $12.35M 10-Q · filed 2026-05-06 | $26.48M derived: sum of 2 quarters · filed 2026-05-06 | $43.08M derived: sum of 3 quarters · filed 2026-05-06 | $48.26M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $14.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $30.73M derived: sum of 2 quarters · filed 2026-02-25 | $35.91M derived: sum of 3 quarters · filed 2026-02-25 | $47.26M 10-K · filed 2026-02-25 |
| 2024-09-30 | $16.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $21.79M derived: sum of 2 quarters · filed 2025-10-28 | $33.13M 10-Q · filed 2025-10-28 | $39.52M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $5.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $16.52M 10-Q · filed 2025-08-06 | $22.91M derived: sum of 3 quarters · filed 2026-02-25 | $25.12M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $11.35M 10-Q · filed 2025-05-06 | $17.74M derived: sum of 2 quarters · filed 2026-02-25 | $19.95M derived: sum of 3 quarters · filed 2026-02-25 | $24.39M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $6.39M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $8.60M derived: sum of 2 quarters · filed 2026-02-25 | $13.04M derived: sum of 3 quarters · filed 2026-02-25 | $17.35M 10-K · filed 2026-02-25 |
| 2023-09-30 | $2.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $6.65M derived: sum of 2 quarters · filed 2024-11-06 | $10.96M 10-Q · filed 2024-11-06 | $16.99M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $4.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $8.75M 10-Q · filed 2024-08-14 | $14.78M derived: sum of 3 quarters · filed 2025-02-25 | $17.21M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $4.31M 10-Q · filed 2024-05-14 | $10.34M derived: sum of 2 quarters · filed 2025-02-25 | $12.77M derived: sum of 3 quarters · filed 2025-02-25 | $12.77M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $6.03M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $8.46M derived: sum of 2 quarters · filed 2025-02-25 | $8.46M derived: sum of 3 quarters · filed 2025-02-25 | $8.46M 10-K · filed 2025-02-25 |
| 2022-09-30 | $2.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $2.43M derived: sum of 2 quarters · filed 2023-11-03 | $2.43M 10-Q · filed 2023-11-03 | $2.43M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $0.00 10-Q · filed 2023-08-08 | $0.00 derived: sum of 3 quarters · filed 2024-02-27 | |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-09 | $0.00 derived: sum of 2 quarters · filed 2024-02-27 | ||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $0.00 10-K · filed 2024-02-27 | ||
| 2021-09-30 | $0.00 10-Q · filed 2022-11-08 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |